‘Basaglar,’ price-competitive biosimilar, launched in Korea

‘Basaglar,’ the first insulin glargine biosimilar in Korea, will be launched.

Lilly Korea and Boehringer Ingelheim Korea held a meeting to celebrate the launch of ‘Basaglar(generic name: insulin glargine 100U/ml),’ a insulin glargine biosimilar, on the 13^th and revealed the Korean diabetes patients’ insulin treatment trend and the product’s clinical efficacy.

Basaglar, the first insulin glarg...